Engineered proline hydroxylase polypeptides

Patent metadata

Field	Value
Publication number	US-9790527-B2
Application number	US-201314399034-A
Country	US
Kind code	B2
Filing date	May 7, 2013
Priority date	May 8, 2012
Publication date	Oct 17, 2017
Grant date	Oct 17, 2017

Abstract

The present disclosure provides engineered proline hydroxylase polypeptides for the production of hydroxylated compounds, polynucleotides encoding the engineered proline hydroxylases, host cells capable of expressing the engineered proline hydroxylases, and methods of using the engineered proline hydroxylases to prepare compounds useful in the production of active pharmaceutical agents. The present disclosure provides engineered proline hydroxylase biocatalysts, polynucleotides encoding the biocatalysts, methods of their preparation, and processes for preparing hydroxylated compounds using these engineered biocatalysts.

First claim

What is claimed is:

1. An engineered polypeptide comprising an amino acid sequence that is at least 95% identical to SEQ ID NO: 2 comprises the substitution of H166Q, wherein the engineered proline hydroxylase has proline hydroxylase activity.

2. The engineered polypeptide of claim 1 further comprising residue differences at one or more residue positions selected from: X2; X3; X4; X5; X9; X13; X25; X26; X29; X30; X36; X42; X52, X57; X58; X59; X66; X92; X95; X103; X112; X115; X116; X121; X131; X150; X151; X225; X230; and X271; wherein the residues at these positions are selected from X2K; X2T; X3S; X4Q; X4L; X4E; X4S; X5I; X5L; X5M; X9I; X13T; X25R; X26T; X29A; X30V; X30P; X36T; X42E; X52P; X57T; X57A; X58A; X59G; X66Q; X86S; X92V; X95M; X103L; X103Q; X112T; X112V; X113E, X115E; X115H; X115D; X115G; X115S; X115A; X116L; X121F; X131Y; X131F; X150S; X151S; X225L; X225Y; X225W; X230V; X270E; X271K; and X271R.

3. The engineered polypeptide of claim 2 , in which the amino acid sequence comprises at least a combination of features selected from:
(a) X103L;
(b) X52P and X255Y;
(c) X4E/L/S and X115A;
(d) X25R and X58A;
(e) X29A;
(f) X115H/D/G and X121F;
(g) X3S and X103L;
(h) X103L and X131Y/F;
(i) X26T and X103L;
(j) X25R, X66Q, X92V and X115E;
(k) X25R, X66Q, X92V, X103L, and X115E; and
(l) X3S, X25R, X66Q, X92V, X103L, and X115E.

4. The engineered polypeptide of claim 2 , which further comprises one or more residue differences as compared to the sequence of SEQ ID NO: 2 at residue positions selected from: X17, X24, X26, X62, X88, X98, X114, X140, X151, X186, X188, and X205.

5. The engineered polypeptide of claim 4 in which the residue differences at residue positions X17, X24, X26, X62, X88, X98, X114, X140, X151, X186, X188, and X205 are selected from X17V, X24R, X24S, X26R, X26W, X62Q, X88R, X98F, X98T, X114N, X140L, X151A, X151H, X186G, X188G, and X205V.

6. The engineered polypeptide of claim 1 , which is capable of converting substrate compound (2), (2S)-piperidine-2-carboxylic acid,

to product compound (1), (2S,5S)-5-hydroxypiperidine-2-carboxylic acid,

under suitable reaction conditions.

7. The engineered polypeptide of claim 6 in which the polypeptide is capable of converting substrate compound (2) to product compound (1) with at least 2 fold the activity of SEQ ID NO:2, optionally, wherein the amino acid sequence comprises one or more features selected from: X3S; X4Q; X4L; X5I; X5L; X24S; X25R; X30P; X66Q; X86S; X92V; X103L; X103Q; X113E;
X115E; X150S; X151S; X225L; and X270E.

8. The engineered polypeptide of claim 1 , which is capable of converting substrate compound (2) to product compound (1) in excess of product compound (la), (2S,3R)-3-hydroxypiperidine-2-carboxylic acid,

wherein the amino acid sequence comprises one or more features selected from: X103L; X115E; and X131Y.

9. The engineered polypeptide of claim 1 , which is capable of forming product compound (1),

in diastereomeric excess of product compound (1R), (2S,5R)-5-hydroxypiperidine-2-carboxylic acid.

10. The engineered polypeptide of claim 1 having proline hydroxylase activity in which the amino acid sequence comprises a sequence selected from the group consisting of SEQ ID NO: 24, 100, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 172, 174, 176, 178, 180, 182, 184, 186, 188, 190, 192, 194, 196, 198, 200, 202, 204, 206, 208, 210, 212, 214, 216, 218, 220, 222, 224, 226, and 228.

Assignees

• Codexis Inc

Inventors

• Chen Haibin
• Bong Yong Koy
• Cabirol Fabien L
• Gohel Prafulchandra Anupam
• Li Tao
• Moore Jeffrey C
• Quintanar-Audelo Martina
• Hong Yang
• Collier Steven J
• Smith Derek

Classifications

• C12P17/12 Primary

  containing a six-membered hetero ring · CPC title

• C12P17/188

  Heterocyclic compound containing in the condensed system at least one hetero ring having nitrogen atoms and oxygen atoms as the only ring heteroatoms (ergot-alcaloids C12P17/183) · CPC title

• C12N9/0071 Primary

  acting on paired donors with incorporation of molecular oxygen (1.14) · CPC title

• C12P13/24

  Proline; Hydroxyproline; Histidine · CPC title

• Y02P20/52

  using catalysts, e.g. selective catalysts · CPC title